Ahmet Sezer

1.1k total citations
40 papers, 276 citations indexed

About

Ahmet Sezer is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ahmet Sezer has authored 40 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 14 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ahmet Sezer's work include Lung Cancer Treatments and Mutations (8 papers), Breast Cancer Treatment Studies (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Ahmet Sezer is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Breast Cancer Treatment Studies (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Ahmet Sezer collaborates with scholars based in United States, Türkiye and Ukraine. Ahmet Sezer's co-authors include Floyd Thoma, Suresh Mulukutla, Lale Altan, Sandeep Jain, Samir Saba, Amr F. Barakat, Yisi Wang, Aditya Bhonsale, Ahmad Masri and Mourad H. Senussi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Ahmet Sezer

31 papers receiving 269 citations

Peers

Countries citing papers authored by Ahmet Sezer

Since Specialization

Citations

This map shows the geographic impact of Ahmet Sezer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmet Sezer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmet Sezer more than expected).

Fields of papers citing papers by Ahmet Sezer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmet Sezer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmet Sezer. The network helps show where Ahmet Sezer may publish in the future.

Co-authorship network of co-authors of Ahmet Sezer

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmet Sezer. A scholar is included among the top collaborators of Ahmet Sezer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmet Sezer. Ahmet Sezer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Omission of axillary dissection after neoadjuvant systemic treatment in initially node-positive HER2-overexpressed and triple-negative breast cancer patients: SENATURK OTHER-NAC study 2025 ·European Journal of Surgical Oncology ·Neslihan Cabıoğlu, (unknown), Abdullah İğci, Cihan Uras, Onur Dülgeroğlu, Güldeniz Karadeniz Çakmak, Ahmet Sezer, Günay Gürleyik, Mustafa Tükenmez, (unknown), Mahmut Müslümanoğlu, Enver Özkurt, (unknown), Mustafa Ümit Uğurlu, (unknown), (unknown), Vahit Özmen, Bahadır M. Güllüoğlu	1
2	Omitting Axillary Dissection in Triple-Negative and HER2-Overexpressed Breast Cancers With Positive Sentinel Lymph Nodes During Upfront Surgery: SENATURK-OTHELLO Study 2025 ·Clinical Breast Cancer ·Neslihan Cabıoğlu, Hasan Karanlık, Vahit Özmen, Mustafa Tükenmez, Abdullah İğci, (unknown), Hande Köksal, (unknown), (unknown), Cihan Uras, Onur Dülgeroğlu, Enver Özkurt, (unknown), Mahmut Müslümanoğlu, (unknown), Ahmet Sezer, Güldeniz Karadeniz Çakmak, (unknown), (unknown), Bahadır M. Güllüoğlu	0
3	Right Ventricular Strain Improves the Echocardiographic Diagnosis and Risk Stratification of Transthyretin Cardiac Amyloidosis Among Other Phenotypes of Left Ventricular Hypertrophy 2024 ·Journal of the American Society of Echocardiography ·(unknown), (unknown), (unknown), Prem Soman, William E. Katz, Ahmet Sezer, Leyla Elif Sade	10
4	Beta blockers are associated with lower all-cause mortality among HFpEF patients 2024 ·Clinical Research in Cardiology ·Joseph Ibrahim, (unknown), Ahmet Sezer, Floyd Thoma, (unknown), Suresh Mulukutla, (unknown), Marc A. Simon, Gavin Hickey	2
5	Medication optimization clinic decreases hospitalizations and mortality for patients with heart failure with reduced ejection fraction 2024 ·SHILAP Revista de lepidopterología ·James C. Coons, (unknown), Michael A. Mathier, Suresh Mulukutla, Floyd Thoma, Ahmet Sezer, Mary Keebler	0
6	Cardiovascular Hospitalizations and Resource Use Following Atrial Fibrillation Ablation 2023 ·Journal of the American Heart Association ·(unknown), Amr F. Barakat, (unknown), Floyd Thoma, Suresh Mulukutla, Ahmet Sezer, Konstantinos N. Aronis, Aditya Bhonsale, Krishna Kancharla, Andrew Voigt, Norman C. Wang, Alaa Shalaby, N.A. Mark Estes, Samir Saba, Sandeep Jain	4
7	Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial 2023 ·Journal of Thoracic Oncology ·Martin Reck, Fabrice Barlési, James C. Yang, Virginie Westeel, Enriqueta Felip, Mustafa Özgüroğlu, Manuel Cobo, Richard Sullivan, Dariusz M. Kowalski, Zoran Andrić, Dae Ho Lee, Ahmet Sezer, Ping Hu, XiaoZhe Wang, Anja von Heydebreck, (unknown), Keyvan Tadjalli Mehr, Keunchil Park	9
8	Conventional Tools for Predicting Satisfactory Response to Neoadjuvant Chemotherapy in HR+/HER2− Breast Cancer Patients 2023 ·Breast Care ·(unknown), Bahadır M. Güllüoğlu, (unknown), (unknown), (unknown), (unknown), Ebru Taştekin, Handan Kaya, (unknown), Hasan Karanlık, Ahmet Sezer, Mustafa Ümit Uğurlu, (unknown), (unknown), Claudiu Mărginean	1
9	Association of pre–left ventricular assist device defibrillator shocks for ventricular arrhythmia with clinical outcomes after left ventricular assist device implantation 2023 ·Heart Rhythm O2 ·(unknown), (unknown), Norman C. Wang, Suresh Mulukutla, Floyd Thoma, Ahmet Sezer, (unknown), Amr F. Barakat, (unknown), (unknown), Konstantinos N. Aronis, Andrew Voigt, Sandeep Jain, Samir Saba, Aditya Bhonsale, N.A. Mark Estes, Mary Keebler, Gavin Hickey, Raveen Bazaz, Krishna Kancharla	2
10	75P Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation 2023 ·Immuno-Oncology Technology ·(unknown), (unknown), (unknown), Ahmet Sezer, (unknown), (unknown), (unknown), (unknown), Giuseppe Gullo, (unknown), Ruben G.W. Quek	2
11	Dofetilide use is not associated with increased mortality in patients with left ventricular hypertrophy and atrial fibrillation 2022 ·Journal of Cardiovascular Electrophysiology ·(unknown), (unknown), (unknown), Ahmet Sezer, Floyd Thoma, Suresh Mulukutla, Aditya Bhonsale, N.A. Mark Estes, Samir Saba, Sandeep Jain, (unknown)	0
12	112P Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation 2022 ·Annals of Oncology ·Igor Bondarenko, Ahmet Sezer, Saadettin Kılıçkap, Mahmut Gümüş, Mustafa Özgüroğlu, (unknown), Xiaodong He, (unknown), Petra Rietschel, Ruben G.W. Quek	1
13	582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1 2022 ·Regular and Young Investigator Award Abstracts ·Saadettin Kılıçkap, Ahmet Sezer, (unknown), Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, (unknown), Giuseppe Gullo, Petra Rietschel, Ruben G.W. Quek	0
14	A Validated Model to Identify Patients With Low Likelihood of High-Risk Coronary Artery Disease Anatomy 2022 ·The American Journal of Cardiology ·Amr F. Barakat, (unknown), Essa Hariri, (unknown), Niyati M. Gupta, Joseph Ibrahim, (unknown), Bo Hu, Ahmet Sezer, Floyd Thoma, Prem Soman, Suresh Mulukutla, Benico Barzilai, Stephen G. Ellis, Wael A. Jaber, Michael B. Rothberg	1
15	Long-term Outcomes of Percutaneous Coronary Intervention in Patients with Prior Coronary Artery Bypass Grafting 2022 ·The Heart Surgery Forum ·(unknown), Edgar Aranda‐Michel, Ahmet Sezer, Suresh Mulukutla, (unknown), Dustin Kliner, Danny Chu, Ibrahim Sultan	0
16	Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories 2021 ·JACC. Clinical electrophysiology ·Amr F. Barakat, Sandeep Jain, Ahmad Masri, Laith Alkukhun, Mourad H. Senussi, Ahmet Sezer, Yisi Wang, Floyd Thoma, Aditya Bhonsale, Samir Saba, Suresh Mulukutla	30
17	TRENDS AND PREDICTORS OF NOAC VERSUS WARFARIN USE FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION 2020 ·Journal of the American College of Cardiology ·(unknown), Ahmet Sezer, Sandeep Jain, Floyd Thoma, Krishna Kancharla, Aditya Bhonsale, Samir Saba, Suresh Mulukutla	2
18	Outcomes of catheter‐directed thrombolysis vs. standard medical therapy in patients with acute submassive pulmonary embolism 2019 ·Pulmonary Circulation ·(unknown), Ahmet Sezer, Floyd Thoma, Michael Sharbaugh, (unknown), Robert Maholic, Efthymios D. Avgerinos, Belinda Rivera‐Lebron, Catalin Toma	18
19	Rotavirus and Adenovirus Incidences in Diarrheas Existing in the Early Childhood 2016 ·SHILAP Revista de lepidopterología ·(unknown), Ahmet Sezer, (unknown)	2
20	Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: Is there a role for radiation therapy? 2011 ·Radiation Oncology ·Ruşen Coşar, Cem Uzal, Füsun Tokatlı, (unknown), Mert Saynak, Nesrin Turan, Sernaz Uzunoğlu, (unknown), Ahmet Sezer, (unknown), (unknown), (unknown), Zafer Koçak	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact